Dry powder formulations of dNase I

US9603907B2 · kind B2 · utility

Assignee

• Protalix Ltd. · IL

Inventors

• Yoseph Shaaltiel · Beit Hillel, IL
• Uri Hanania · Carmiel, IL
• Tali Kizhner · Sachnin, IL
• Yulia Matiuhin · Pardes Hana-Karkur, IL
• Liat Fux · Kiryat Motzkin, IL
• Avidor Shulman · Rakefet, IL

Key dates

• Filing date: Jan 31, 2013
• Grant date: Mar 28, 2017
• Expiry date: Jan 31, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Y302/01052
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

DNase I formulations for pulmonary administration and, more particularly, but not exclusively, a dry powder formulation comprising, as an active ingredient, human DNase I, methods, dry powder inhalation devices and systems for the therapeutic use thereof are provided.